Skip to main content

BOT

Botanix (ASX: BOT) looks to be suffering (still) from the Donald Trump announcement that didn't have anything to do with them. That announcement set the whole biotech sector on edge and many companies are still recovering. Add to that what looks like fairly ordinary results so far and BOT has dropped significantly. All holders can do now is hold on. There should be good results coming through America's summer, and that should boost the share price.

Also, BIT may look at selling their Sofdra division to big pharma as it falls outside the scope of the punishing Trump announcment and allows big pharma to capitalise on something. This is only my thinking and I have not heard anything like this come out of BOT.

Comments

Post a Comment

Popular posts from this blog

A Couple of Updates

 Well, it's Monday morning and the week has started with a bang. First, PFE announced that there was an unexpected problem with their test drill and they have had to abandon that and go to a new test drill site. A delay, but no real issue apart from that. And the market hated that. Good news for those wanting to buy, not so good for existing holders. IMC released their AGM presentation which indicates that there will be some news in December and then a very busy (and hopefully productive) 2025. Sales are good and continuing to get better and better.
Post a Comment
Read more

2025 - an early start

 Ok., so here we go on my Trump-era goal. Just bought MXR (yes, on the ASX). AAR wants to take them over at 7 cents as a scrip payment (paying in AAR shares instead of cash). The current share price is 6.3 cents. So that should be a quick 10% gain. However... this does look like a lowball offer and may yet be increased. MXR has great assets and AAR already owns almost 20% of MXR. So AAR is committed to a deal and that may just attract other attention. It looks like a no-brainer to start 2025. Yes, there is always some risk, but this one looks pretty good. I have done a bit more research and have some exciting thoughts, including one that looks a little like another WGO (which returned handsomely on a takeover). More news coming as I do more reseach.  Another one that looks good for a quick profit is GES, but as I write this, there are no shares at the right price (.05).
Post a Comment
Read more

Out of 2

 I ahd some bills to pay and these 2 got the chop: PFE - such promise, such disappointmen IMC - I always had some ethical problems with this one.  But there it is. Bills paid, and a little left over to find something new with. 
Post a Comment
Read more